Dr reddy’s Laboratories has announced that its anti covid19 oral drug molnupiravir could hit the market as early as next week in India.
Dr Reddy’s molnupiravir which will be launched under the brand name -Molflu will cost 35 per capsule of 200mg and the complete course of 40 capsules will cost Rs 1400, which makes it the most affordable molnupiravir to be launched in the Indian market yet, the company said.
Dr Reddy’s had entered into a non-exclusive voluntary licensing agreement with MSD to manufacture and supply molnupiravir to India and over 100 low and middle-income countries late last year.
Dr Reddy’s received emergency-use authorisation from the Drugs Controller General of India (DCGI) to manufacture and market molnupiravir capsules 200mg for the treatment of adult patients with COVID19, with blood oxygen level greater than 93% and who have a high risk of progression of the disease including hospitalisation or death on December 28, 2021, the company had informed in an official statement.
“Molnupiravir is a continuation of our constant effort since the start of the pandemic to ensure access to every possible treatment option against COVID-19 from prevention to mild, moderate and severe disease for patients in India and around the world,” G.V. Prasad, Co-Chairman and Managing Director, Dr Reddy’s Laboratories said.
“The approval to launch molnupiravir is an important development not only as a treatment option but also for the collaborative manner in which Indian pharma companies came together. Throughout the pandemic, we have sought to create diverse collaborations and partnerships to meet unmet medical needs of as many patients as possible globally,” he added.